Breast Cancer Liquid Biopsy Market to Reach US$7.98 Billion by 2031 at 23.2% CAGR, Driven by cfDNA & CTC Assays, Early Screening Applications, and Key Players F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and Illumina Inc.

The Breast Cancer Liquid Biopsy Market reached US$ 1.6 billion in 2023 and is expected to reach US$ 7.98 billion by 2031, growing at a CAGR of 23.2% from 2024 to 2031 as demand for non‐invasive cancer diagnostics and real‐time treatment monitoring accelerates globally.

Growth is supported by rising demand across key product segments such as reagents & kits and instruments, driven by increasing prevalence of breast cancer, technological advancements in circulating biomarkers like circulating tumor cells (CTCs) and cell‐free DNA (cfDNA), and the expanding adoption of liquid biopsy for early screening and personalized treatment selection. Integration of advanced molecular profiling, microfluidics, and AI‐assisted analytics enhances detection accuracy and clinical utility, further accelerating market expansion. Additionally, growing awareness of early diagnosis benefits, supportive healthcare initiatives, and investments in precision oncology continue to propel broad adoption of breast cancer liquid biopsy solutions and services worldwide.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/breast-cancer-liquid-biopsy-market?sindhuri

Breast Cancer Liquid Biopsy Market: Competitive Intelligence
F. Hoffmann‐La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health Inc., QIAGEN N.V., and others.
The Breast Cancer Liquid Biopsy Market is strongly driven by leading diagnostics, life‐science tools, and precision oncology companies such as F. Hoffmann‐La Roche Ltd., Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V., who provide advanced liquid biopsy solutions including circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) assays, next‐generation sequencing (NGS) panels, digital PCR platforms, and comprehensive cancer genomic profiling tools that enable non‐invasive detection, monitoring, and treatment selection for breast cancer patients. These technologies support early disease identification, real‐time therapy response evaluation, and minimal residual disease (MRD) tracking, improving clinical decision‐making and personalized oncology care.

Rising breast cancer incidence globally, expanding adoption of liquid biopsy as a minimally invasive diagnostic and monitoring alternative to traditional tissue biopsies, increased emphasis on precision medicine and biomarker‐driven treatment strategies, and ongoing investments in oncology R&D and clinical validation are key factors fueling market demand. Technological advancements in high‐sensitivity assays, integration of AI‐assisted analytics, and expanded use of ctDNA/CTC‐based tests across hospitals, reference laboratories, and research institutions further strengthen adoption.

These companies' complementary strengths broad sequencing platforms and genomic profiling expertise from Illumina and Thermo Fisher; extensive clinical diagnostics, liquid biopsy test portfolios, and commercialization networks from Roche and QIAGEN; highly sensitive ctDNA assays and precision oncology tools from Guardant Health; along with contributions from Bio‐Rad Laboratories Inc., Biocept Inc., Myriad Genetics, Inc., Natera, Inc., Exact Sciences Corporation, NeoGenomics Laboratories, and other innovators enhance competitive positioning across global breast cancer liquid biopsy markets. Strategic focus areas include development of expanded multi‐gene NGS panels, AI and machine‐learning‐enabled interpretation platforms, real‐world clinical evidence generation, regulatory approvals, payer engagement for reimbursement pathways, and partnerships with healthcare systems and academic research centers to accelerate clinical adoption and improve patient outcomes.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/breast-cancer-liquid-biopsy-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: Guardant Health expanded its breast cancer liquid biopsy portfolio in the U.S., introducing advanced circulating tumor DNA (ctDNA) assays for early detection, treatment monitoring, and recurrence assessment.
✅ May 2025: Biocept, Inc. launched next-generation liquid biopsy panels for breast cancer, integrating multi-gene profiling to guide personalized therapy decisions.
✅ 2025: Increasing adoption of minimally invasive diagnostics and precision oncology initiatives in major cancer centers drove strong demand for liquid biopsy solutions across North America.

Recent Key Developments - Europe
✅ July 2025: Qiagen N.V. introduced high-sensitivity breast cancer liquid biopsy kits in Europe, enabling early detection and monitoring of metastatic progression.
✅ Early 2026: F. Hoffmann-La Roche AG expanded its clinical trial partnerships to validate liquid biopsy applications for treatment response and minimal residual disease assessment in breast cancer patients.
✅ 2025: Growing emphasis on personalized medicine, regulatory approvals, and integration of liquid biopsy into standard clinical workflows supported market growth across Europe.

Recent Key Developments - Asia-Pacific
✅ June 2025: Nanjing Geneseeq Technology launched liquid biopsy testing services for breast cancer detection and therapy monitoring in China and Southeast Asia.
✅ 2025: Sysmex Corporation expanded breast cancer liquid biopsy offerings in Japan, integrating ctDNA and circulating tumor cell (CTC) analysis to support precision oncology programs.
✅ 2025-2026: Rising breast cancer prevalence, increased awareness, and growing adoption of minimally invasive diagnostic tools across India, China, Japan, and Australia fueled regional market growth.

Recent Key Developments - Product & Technology Innovation
✅ High-Sensitivity ctDNA & CTC Assays: Development of assays capable of detecting low-frequency mutations and monitoring treatment response in real time.
✅ Multi-Gene & Multi-Omics Panels: Integration of genomic, transcriptomic, and epigenetic markers for improved diagnostic accuracy and personalized therapy guidance.
✅ AI & Digital Integration: Advanced bioinformatics and AI-driven platforms for data interpretation, risk stratification, and clinical decision support in breast cancer management.

✅ 1. M&A / Strategic Activity
Recent strategic acquisitions and collaborations shaping the breast cancer liquid biopsy market:
Roche - Expansion of personalized oncology diagnostics
Roche continued strengthening its liquid biopsy portfolio through strategic collaborations and acquisitions of specialized molecular diagnostics firms. These moves bolster its ability to offer comprehensive blood‐based tumor profiling, including circulating tumor DNA (ctDNA) assays relevant to breast cancer management.

Guardant Health - Partnerships for genomic testing access
Guardant Health expanded partnerships with oncology centers and payers in key markets, including Japan and Europe, to broaden access to its Guardant360 liquid biopsy test, which detects actionable genomic alterations in metastatic breast cancer and supports therapy selection.
Exact Sciences - Acquisition of Cologuard and collaboration expansion
Exact Sciences, while best known for colorectal cancer screening, expanded its oncology diagnostics roadmap via acquisition of predictive analytics and molecular testing partners, potentially enabling future integration of breast cancer liquid biopsy offerings.
Illumina - Strategic alliances with biopharma
Illumina formed alliances with biopharmaceutical companies to integrate its next‐generation sequencing (NGS) platforms with liquid biopsy workflows for early detection and minimal residual disease (MRD) monitoring in breast cancer.

✅ 2. New Product Launches & Regulatory Milestones
Recent launches, clearances, and clinical validation progress in breast cancer liquid biopsy tests:
Guardant Health - Guardant360 CDx updates
Guardant Health continued to obtain regulatory acceptances and reimbursement support for Guardant360 CDx, a comprehensive liquid biopsy test used for genomic profiling in metastatic breast cancer to guide targeted therapy decisions.
Roche - Oncomine and AVENIO ctDNA expanded use
Roche expanded label indications for the AVENIO ctDNA analysis kit and Oncomine panels, solidifying clinical evidence for use in detecting actionable mutations and supporting therapy monitoring in breast cancer patients.
Foundation Medicine (a subsidiary of Roche) - FoundationOne® Liquid CDx
Foundation Medicine expanded real‐world data supporting FoundationOne® Liquid CDx in breast cancer, reinforcing its use in identifying genomic alterations for targeted therapy and clinical trial stratification.
Exact Sciences - Early detection research programs
Exact Sciences advanced clinical validation for blood‐based assays that incorporate breast cancer markers, aiming to develop multi‐cancer early detection (MCED) liquid biopsy tests with improved sensitivity for breast malignancies.

✅ 3. R&D & Technological Advancements
ctDNA & MRD Detection Enhancement
R&D in the breast cancer liquid biopsy space is heavily focused on increasing sensitivity and specificity of circulating tumor DNA (ctDNA) assays to enable earlier detection of recurrence, monitoring therapeutic response, and assessing minimal residual disease (MRD) with higher precision.
Multi‐Omics Integration
Innovations are progressing toward multi‐omics liquid biopsy platforms, combining genomic, epigenomic (methylation), and proteomic markers to improve diagnostic accuracy and therapeutic insights in breast cancer.
Single‐Cell & Exosome Profiling
Advanced liquid biopsy research includes single‐cell sequencing and exosome/EV (extracellular vesicle) profiling to capture heterogeneous tumor signals that may be missed by ctDNA alone, supporting more comprehensive patient stratification.
AI & Machine Learning in Interpretation
Machine learning and AI‐driven analytics are being incorporated into liquid biopsy data interpretation pipelines to distinguish tumor signal from noise, identify emerging resistance mutations, and offer predictive insights into treatment response patterns.

Market Drivers & Emerging Trends
» Increasing Breast Cancer Prevalence - Rising incidence of breast cancer globally, particularly in aging populations, is driving demand for non‐invasive monitoring and early detection tools.
» Shift Toward Precision Oncology - Clinicians increasingly adopt liquid biopsy to tailor targeted therapies and adjust regimens based on evolving genomic profiles.
» Minimally Invasive Testing Preference - Liquid biopsies offer a less invasive alternative to tissue biopsies, reducing procedural risk and enabling serial monitoring over time.
» Clinical Evidence & Reimbursement Support - Accumulating clinical validation data and expanded payer support are improving adoption and accessibility of liquid biopsy tests in routine care.
» Multi‐Cancer Early Detection Development - Growth of MCED tests positions liquid biopsy as part of broader cancer screening programs that include breast cancer signatures.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=breast-cancer-liquid-biopsy-market?sindhuri

Segments Covered in the Breast Cancer Liquid Biopsy Market:
By Product Type
The market is segmented into reagents & kits (60%) and instruments (40%).Reagents & kits dominate due to widespread use in sample preparation, biomarker detection, and assay standardization. Instruments are essential for analysis and detection, including PCR systems, next-generation sequencing platforms, and microfluidics, but represent a smaller share as they are often high-cost capital equipment.

By Circulating Biomarkers
Circulating biomarkers include circulating tumor cells (CTCs) (35%), circulating cell-free DNA (cfDNA) (40%), extracellular vesicles (15%), and others (10%).cfDNA dominates due to its high sensitivity, non-invasiveness, and effectiveness in early detection and monitoring therapy response. CTCs are widely used for prognostic and therapeutic monitoring. Extracellular vesicles are an emerging segment with potential in predictive diagnostics. Other biomarkers include microRNAs and exosomal DNA.

By Application
Applications comprise early screening (50%) and treatment selection (50%).Early screening is a major driver as liquid biopsy offers minimally invasive detection for high-risk populations. Treatment selection is increasingly significant for precision oncology, enabling therapy personalization based on biomarker profiling and monitoring disease progression.

By End-Users
End-users include hospitals (40%), diagnostic centers (35%), research and educational institutions (15%), and others (10%).Hospitals dominate due to integration of liquid biopsy into clinical workflows for diagnosis and monitoring. Diagnostic centers contribute significantly through specialized testing services. Research and educational institutions drive innovation and clinical studies, while others include pharmaceutical companies and contract research organizations.

Regional Analysis
North America - 40% Share
North America leads due to advanced oncology research, early adoption of liquid biopsy technologies, and strong healthcare infrastructure in the U.S. and Canada.

Europe - 25% Share
Europe holds a significant share supported by growing cancer prevalence, well-established diagnostic networks, and increasing adoption of precision medicine in Germany, the U.K., France, and Italy.

Asia-Pacific - 20% Share
Asia-Pacific is witnessing rapid growth due to rising breast cancer incidence, expanding healthcare facilities, and increasing awareness in China, Japan, India, and South Korea.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.